Despite a significant correction in the broader market today, shares of CarTrade Tech, Concord Biotech, and Apar Industries demonstrated remarkable resilience, surging by up to 8% in early trading. The gains were driven by specific positive developments for each company, contrasting sharply with declines seen in major indices like the Sensex and Nifty.
CarTrade Tech Sees Strong Rally on Brokerage Upgrade
CarTrade Tech shares climbed 8% to Rs 1931, up from their previous close of Rs 1795.20. This surge followed an upgrade from Kotak Institutional Equities, which revised its rating on the online auto platform to "buy" from "sell" and significantly increased its price target. The brokerage firm now projects a target of Rs 2,300 per share, a substantial jump from the previous Rs 1,800.
Kotak's positive outlook is based on CarTrade's robust dealer database and its expanding suite of value-added offerings, which are expected to mitigate potential impacts from AI models. The upgrade also considers a higher valuation for OLX, anticipating steady gross merchandise value (GMV) growth, improved monetization strategies, and enhanced margins.
Concord Biotech Gains on USFDA Approval
Concord Biotech's stock also experienced a significant uptick, rising 8.36% to Rs 1264.45. The pharmaceutical company announced it had received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
Mycophenolate Mofetil is a crucial antimetabolite immunosuppressant. It is prescribed for the prophylaxis of organ rejection in adult and pediatric patients (three months and older) who have received allogeneic kidney, heart, or liver transplants, typically used in combination with other immunosuppressive agents.
Apar Industries Hits 52-Week High Following Robust Q4 Results
Apar Industries shares reached a fresh 52-week high, advancing 6.21% against its previous close. The climb comes on the heels of the company's announcement of its consolidated financial results for the fourth quarter of fiscal year 2026.
The company reported a net profit of Rs 253 crore for the quarter, marking a 1.2% increase compared to Rs 250 crore in the same period last year. Furthermore, Apar Industries saw a substantial 26.74% year-on-year rise in consolidated revenue from operations, reaching Rs 6,602.81 crore, underscoring strong operational performance.
Market Context: Individual Gains Defy Broader Downturn
These individual stock surges occurred even as the broader Indian market faced headwinds. The Sensex plunged by 700 points to 73,949, and the Nifty shed 185 points, settling at 23,299 in early trading. The exceptional performance of CarTrade Tech, Concord Biotech, and Apar Industries highlights specific company-centric catalysts driving investor confidence.